Jump to content

Myxofibrosarcoma

From Wikipedia, the free encyclopedia
(Redirected from Draft:Myxofibrosarcoma)
Myxofibrosarcoma
SpecialtyDermatology, Dermatopathology, Pathology, Surgical oncology, Oncology
TypesEpithelioid myxofibrosarcoma
CausesUnknown
PrognosisGuarded

Myxofibrosarcoma (MFS), although a rare type of tumor, is one of the most common soft tissue sarcomas, i.e. cancerous tumors, that develop in the soft tissues of elderly individuals.[1] Initially considered to be a type of histiocytoma termed fibrous histiocytoma or myxoid variant of malignant fibrous histiocytoma,[2] Angervall et al. termed this tumor myxofibrosarcoma in 1977.[3] In 2020, the World Health Organization reclassified MFS as a separate and distinct tumor[4] in the category of malignant fibroblastic and myofibroblastic tumors.[5]

MFS tumors are often treated by surgical resection. However, these tumors have high recurrence rates at the sites of their resections.[6] Local recurrences followed by surgical resections may be repeated multiple times but during these cycles MFS tumors often progress from a lower grade to a higher more aggressive grade, metastasize, and become life-threatening.[4] An uncommon variant of the MFS tumors termed epithelioid myxofibrosarcoma is even more likely to follow an aggressive, recurrent, metastasizing, and life-threatening course than the more common form of the MFS tumors.[6]

Presentation

[edit]

MFS usually afflicts individuals in their fifth to seventh decades of life although uncommon cases occur in adults outside of this age range[7] In one large study, MFS was diagnosed in individuals 21 to 96 years old (median age, 66 years old).[4] Most studies have diagnosed MFS slightly more often in men than women[7] but one large study conducted in France found it to be 50% more common in men.[8] Individuals with MFS present with a tumor located in an extremity (77% of cases, usually in the lower extremity), trunk (12% of cases), and head and neck areas (3% of cases).[7] Rarely, these tumors have presented in the breast, heart, paratesticular region (i.e. area inside the scrotum including the epididymis the spermatic cord along with its coverings),[8] eye,[9] bone, liver, or multiple sites concurrently.[10] Primary tumors presenting in the abdominal cavity, retroperitoneum, or pelvis have been diagnosed as MFS[6] but larger studies indicate that these tumors are far more likely to be dedifferentiated liposarcomas.[6][11] MFS tumors usually develop as painless, slowly enlarging masses in a muscle, skin (usually below the fascia i.e. a sheet of connective tissue, primarily collagen, running beneath the skin), or one of the non-cutaneous areas described above.[7] In one study of 69 FBS cases 36 were <5 cm, 23 were between 5 and 10 cm, and 19 were > 10 cm in diameter with the largest tumor being 27 cm.[12] MFS tumors often infiltrate along vascular and fascial planes, are incompletely removed at surgery, and consequently recur at the surgical site.[13] Recurrences of the MFS at the site of surgery have developed in 16% to 57% of patients with a significant proportion (25%–52%) recurring multiple times.[7] In one study, recurrences developed between 2 and 82 months (median 53 months) following primary surgery and metastatic disease developed in 23% of patients within 2 to 77 months (median 10 months) following primary surgery.[4] Recurrent tumors tend to be more aggressive and have a much greater tendency to metastasize than primary MFS tumors.[4] In one study, metastatic disease was detected in 23% of patients and occurred at a median of 10 months (range, 2–77 months) after resection of the primary tumor. In a review of multiple studies, the risk of developing metastases for lower grade MFS (defined in the following section) was <5% and for higher grade tumors was 25–30%.[11] MFS metastasize most commonly to the lungs, bone, and lymph-nodes.[4]

Individuals with the epithelioid variant of FBS generally present with a tumor in the limbs; the tumors tend to be somewhat larger, more aggressive, and more likely to metastasize than the tumors in non-variant cases.[7][14] At least 50% of patients with this variant have developed metastases.[6][11]

Pathology

[edit]

The microscopic histopathology of hematoxylin and eosin stained FBS tumors varies. Lower-grade MFS tissues consist of scattered large, variability-sized and spindle-shaped-to-variably-shaped tumor cells with darkly stained nuclei. Overall, lower-grade tumors contain relatively few cells within a distinctive myxoid (i.e. more blue or purple compared to normal connective tissue because of excessive uptake of the hematoxylin stain) connective tissue background that contains curvilinear, thin-walled blood vessels.[4] Higher grade FBS tumors consist of relatively large sheets of these spindle-shaped/vatiably-shaped cells in a similar myxoid background containing thin-walled curvilinear blood vessels.[6][4] Pseudo-lipoblasts (i.e. multivacuolated cells resembling lipoblasts but having vacuoles filled with mucin rather than lipids) are apparent in both lower grade and higher grade tumors.[4] Epithelioid FBS tumors are highly cellular lesions consisting of diffuse proliferations of extremely large, polygonal-shaped epithelioid cells set in a myxoid connective tissue background similar to that seen in the other types of FBS.[15] Epithelioid myxofibrosarcomas appear to behave more aggressively than myxofibrosarcomas dominated by spindle-shaped/variably-shaped cells.[7] While the cells in most types of tumors express specific marker proteins that help in diagnosing them, the tumor cells in FBS[4] and its epithelioid variant[14] have not yet been found to express marker proteins that are sufficiently specific to support either diagnosis.

Chromosome and gene abnormalities

[edit]

Most cases of MFS have tumor cells that contain complex chromosome and/or gene abnormalities[7] including ring chromosomes (i.e. chromosome whose ends are fused together to form a ring), double minutes (i.e. small fragments of extrachromosomal DNA), chromosomes with deletions of part of their genetic material, and chromosome translocations (i.e. abnormal switches in genetic material between different chromosomes). There were no apparent differences in these abnormalities between lower grade and higher grade tumors but their numbers were higher and more prevalent in recurrent tumors.[16] These forms of chromosome/gene cytogenetic alterations are commonly found in various tumor types regardless of their grade or severity.[7] Tumor cell mutations or deletions in the NF1 gene occur ~10% of MFS cases while mutations in the CDKN2A/CDKN2B and amplifications in the CDK6, CCND1, and MDM2 genes occur in rare MFS cases.[1] While the cells in many tumor types express specific chromosome/gene abnormalities that help in determining their diagnoses, the cited chromosome and gene abnormalities discovered in TBS tumor cells have not yet been found specific enough to be of help in diagnosing MFS.[4] The chromosome/gene abnormalities have not yet been defined in the epithelioid variant of MFS.

Diagnosis

[edit]

The diagnosis of MBS is heavily dependent on the presentation and histopathology of its tumors.[7] Of particular importance, the presence of pseudo-lipoblasts in a myxoid sarcoma-like background is an extremely strong indicator that the tumor is a MFS.[6] and tumors with a myxofibrosarcoma-like histopathology that initiate in the retroperitoneum, abdominal cavity, or pelvis are nearly always dedifferentiated liposarcomas.[6][11] Magnetic resonance imaging (MRI) has been helpful in diagnosing MBS. On T2-weighted MRI, 81% of MFS tumors give a tail sign, i.e. a multidirectional signal spreading away from the main mass along a facial plane (i.e. a line or band of connective tissue). Among all myxoid-predominant tissue lesions, this MRI method diagnoses MBS with a specificity of 79% to 90%. This MRI finding is also extremely valuable for gauging the extent and depth of surgery needed to completely remove MBS tumors.[7]

Treatment and prognosis

[edit]

The recommended treatment for individuals presenting with localized MFS tumors is radical surgical resection.[13] The resection should include a 2 cm margin of soft tissue surrounding the tumor, with planned resection of the entire area as defined by MRI-detected increased signals on T2-weighted images. This is done to ensure that all tumor tissue is removed in order to avoid the high risks of local recurrences and worsening prognoses.[7] Historically, about 10% of patients treated with radical surgery developed recurrences at the surgical site and a significant number of these patients developed metastatic disease. Consequently, adjuvant radiotherapy has been used to help reduce these recurrences and metastatic transformations. For patients with a limb tumor that cannot be resected (less than 5% of all cases)), limb amputation is the treatment of choice.[7] Recurrent and metastatic MFS first-line treatment has employed two chemotherapy drugs, anthracycline and Ifosfamide, while second-line treatment has employed two other chemotherapy drugs, gemcitabine and paclitaxel.[17] Triple chemotherapy drug treatment (adriamycin, ifosfamide, and dacarbazine) has also been used to treat MFS.[18] However, there are no randomized clinical trials evaluating the efficacy of these or other chemotherapy drugs in the treatment of inoperable or metastatic MFS and none of the uncontrolled studies have demonstrated a benefit in improving the overall survival in MFS.[7] Current drug therapies that are or may soon be tried in treating MFS include angiogenesis inhibitors and immunotherapeutics such as Bevacizumab and Nivolumab.[17]

In one review of 109 individuals with MFS: overall survival for the entire group was 80% at 3 years and 76% at 5 years; local recurrence-free survival was 95% at 3 years and 88% at 5 years; median survival following local recurrence was 68 months; distant metastasis-free survival was 78% at 3 and 77% at 5 years; and 18 of 25 patients (72%) died of metastatic disease during a median follow-up time of 42 months for the overall review period of study.[4] In three large studies, overall 5 year disease-specific survival times (i.e. the percentage of patients surviving 5 years excluding death due to any other causes than MFS from this count) were 51%, 73%, and 96%.[7]

References

[edit]
  1. ^ a b Martínez-Trufero J, Cruz Jurado J, Gómez-Mateo MC, Bernabeu D, Floría LJ, Lavernia J, Sebio A, García Del Muro X, Álvarez R, Correa R, Hernández-León CN, Marquina G, Hindi N, Redondo A, Martínez V, Asencio JM, Mata C, Valverde Morales CM, Martin-Broto J (September 2021). "Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I". Cancer Treatment Reviews. 99: 102259. doi:10.1016/j.ctrv.2021.102259. ISSN 0305-7372. PMID 34311246.
  2. ^ Weiss SW, Enzinger FM (April 1977). "Myxoid variant of malignant fibrous histiocytoma". Cancer. 39 (4): 1672–85. doi:10.1002/1097-0142(197704)39:4<1672::aid-cncr2820390442>3.0.co;2-c. PMID 192434. S2CID 29351227.
  3. ^ Angervall L, Kindblom LG, Merck C (March 1977). "Myxofibrosarcoma. A study of 30 cases". Acta Pathologica et Microbiologica Scandinavica, Section A. 85A (2): 127–40. doi:10.1111/j.1699-0463.1977.tb00410.x. PMID 15396.
  4. ^ a b c d e f g h i j k l Gilg MM, Sunitsch S, Leitner L, Bergovec M, Szkandera J, Leithner A, Liegl-Atzwanger B (October 2020). "Tumor-associated mortality and prognostic factors in myxofibrosarcoma - A retrospective review of 109 patients". Orthopaedics & Traumatology, Surgery & Research. 106 (6): 1059–1065. doi:10.1016/j.otsr.2020.04.017. PMID 32778437. S2CID 225432867.
  5. ^ Sbaraglia M, Bellan E, Dei Tos AP (April 2021). "The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives". Pathologica. 113 (2): 70–84. doi:10.32074/1591-951X-213. PMC 8167394. PMID 33179614.
  6. ^ a b c d e f g h Hornick JL (December 2018). "Subclassification of pleomorphic sarcomas: How and why should we care?". Annals of Diagnostic Pathology. 37: 118–124. doi:10.1016/j.anndiagpath.2018.10.006. PMID 30340082. S2CID 53008610.
  7. ^ a b c d e f g h i j k l m n o Roland CL, Wang WL, Lazar AJ, Torres KE (October 2016). "Myxofibrosarcoma". Surgical Oncology Clinics of North America. 25 (4): 775–88. doi:10.1016/j.soc.2016.05.008. PMID 27591498.
  8. ^ a b Amadeo B, Penel N, Coindre JM, Ray-Coquard I, Ligier K, Delafosse P, Bouvier AM, Plouvier S, Gallet J, Lacourt A, Coureau G, Monnereau A, Mathoulin-Pélissier S, Desandes E (March 2020). "Incidence and time trends of sarcoma (2000-2013): results from the French network of cancer registries (FRANCIM)". BMC Cancer. 20 (1): 190. doi:10.1186/s12885-020-6683-0. PMC 7059296. PMID 32138705.
  9. ^ Pujari A, Ali MJ, Honavar SG, Mittal R, Naik M (2014). "Orbital myxofibrosarcoma: a clinicopathologic correlation of an extremely rare tumor". Ophthalmic Plastic and Reconstructive Surgery. 30 (5): e111–3. doi:10.1097/IOP.0b013e3182a230cc. PMID 24833459.
  10. ^ Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E, Barisella M, Sangalli C, Mariani L, Casali PG, Gronchi A (March 2011). "Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution". Annals of Surgical Oncology. 18 (3): 720–5. doi:10.1245/s10434-010-1341-4. PMID 20878245. S2CID 9711352.
  11. ^ a b c d Sioletic S, Dal Cin P, Fletcher CD, Hornick JL (January 2013). "Well-differentiated and dedifferentiated liposarcomas with prominent myxoid stroma: analysis of 56 cases". Histopathology. 62 (2): 287–93. doi:10.1111/j.1365-2559.2012.04348.x. PMID 23020289. S2CID 25393792.
  12. ^ Scoccianti G, Ranucci V, Frenos F, Greto D, Beltrami G, Capanna R, Franchi A (July 2016). "Soft tissue myxofibrosarcoma: A clinico-pathological analysis of a series of 75 patients with emphasis on the epithelioid variant". Journal of Surgical Oncology. 114 (1): 50–5. doi:10.1002/jso.24250. PMID 27076198. S2CID 13082675.
  13. ^ a b Widemann BC, Italiano A (January 2018). "Biology and Management of Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, and Malignant Peripheral Nerve Sheath Tumors: State of the Art and Perspectives". Journal of Clinical Oncology. 36 (2): 160–167. doi:10.1200/JCO.2017.75.3467. PMC 5759316. PMID 29220302.
  14. ^ a b Dey B, Srinivas BH, Badhe B, Nachiappa Ganesh R, Gochhait D, Toi PC, Jinkala S (December 2020). "Malignant Epithelioid Soft Tissue Tumours- A Pathologist's Perspective With Review of Literature". Cureus. 12 (12): e12263. doi:10.7759/cureus.12263. PMC 7834554. PMID 33520482.
  15. ^ Wakely PE (2021). "Cytopathology of myxofibrosarcoma: a study of 66 cases and literature review". Journal of the American Society of Cytopathology. 10 (3): 300–309. doi:10.1016/j.jasc.2020.09.004. PMID 33041221. S2CID 222299645.
  16. ^ Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R (March 2006). "Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model". Modern Pathology. 19 (3): 407–16. doi:10.1038/modpathol.3800550. PMID 16415793.
  17. ^ a b Song L, Pan D, Zhou R (November 2020). "Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature". Molecular and Clinical Oncology. 13 (5): 54. doi:10.3892/mco.2020.2124. PMC 7468213. PMID 32905214.
  18. ^ Look Hong NJ, Hornicek FJ, Raskin KA, Yoon SS, Szymonifka J, Yeap B, Chen YL, DeLaney TF, Nielsen GP, Mullen JT (January 2013). "Prognostic factors and outcomes of patients with myxofibrosarcoma". Annals of Surgical Oncology. 20 (1): 80–6. doi:10.1245/s10434-012-2572-3. PMC 3837421. PMID 22890594.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Myxofibrosarcoma&oldid=1194842794"